{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"The relationship of treatment to overall survival will be assessed. The number of death events in the treatment arm is reported.","groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV","id":"OG000","title":"Arm I (Paclitaxel, Carboplatin)"},{"description":"Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\nBleomycin Sulfate: Given IV\n\nCisplatin: Given IV\n\nEtoposide Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent to Treat","reportingStatus":"POSTED","timeFrame":"From start of treatment to time of death or the date of last contact, assessed up to 10 years. Median follow-up time was 48 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Participants"}